Joelma Maria de Araújo Andrade

Joelma Maria de Araújo Andrade

Auto-generated profile, based on publicly available information

Joelma Maria de Araújo Andrade

Hemocentro Dalton Cunha, Brasil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2016 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
COClaudio Bs Oliveira
Claudio Bs Oliveira
YMYwlliane Meurer
Ywlliane Meurer
JAJoelma Ma Andrade
Joelma Ma Andrade
MCMaria Esm Costa
Maria Esm Costa
MAMilena MC Andrade
Milena MC Andrade
VAValter Andrade-Neto
Valter Andrade-Neto
Toxoplasma gondii is the causative protozoan agent of toxoplasmosis, which is a common infection that is widely distributed worldwide. Studies revealed stronger clonal strains in North America and Europe and genetic diversity in South American strains. Our study aimed to differentiate the pathogenicity and sulfadiazine resistance of three T. gondii isolates obtained from livestock intended for human consumption. The cytopathic effects of the T. gondii isolates were evaluated. The pathogenicity was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) using a CS3 marker and in a rodent model in vivo. Phenotypic sulfadiazine resistance was measured using a kinetic curve of drug activity in Swiss mice. IgM and IgG were measured by ELISA, and the dihydropteroate synthase (DHPS) gene sequence was analysed. The cytopathic effects and the PCR-RFLP profiles from chickens indicated a different infection source. The Ck3 isolate displayed more cytopathic effects in vitro than the Ck2 and ME49 strains. Additionally, the Ck2 isolate induced a differential humoral immune response compared to ME49. The Ck3 and Pg1 isolates, but not the Ck2 isolate, showed sulfadiazine resistance in the sensitivity assay. We did not find any DHPS gene polymorphisms in the mouse samples. These atypical pathogenicity and sulfadiazine resistance profiles were not previously reported and served as a warning to local health authorities.

1 July 2016 in Acta Tropica
Verified
Journal Article
Closed access
MCMaria Eduarda S.M. Costa
Maria Eduarda S.M. Costa
COClaudio Bruno S. Oliveira
Claudio Bruno S. Oliveira
JAJoelma Maria de A. Andrade
Joelma Maria de A. Andrade
TMThatiany A. Medeiros
Thatiany A. Medeiros
VNValter F. Andrade Neto
Valter F. Andrade Neto
DLDaniel C Lanza
Daniel C Lanza

1 September 2020 in Brazilian Journal of Biology
Verified
Journal Article
Open access
PDF file
DCDaniel Campos
Daniel Campos
COClaudio Bruno Silva de Oliveira
Claudio Bruno Silva de Oliveira
JAJ. M. A. Andrade
J. M. A. Andrade
JOJonas Ivan Nobre Oliveira
Jonas Ivan Nobre Oliveira
The current COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) poses a threat to global health owing to its high rate of spread and severe forms of respiratory infection. The lack of vaccines and antivirals prevents clinical strategies against the disease, creating an emerging need for the development of safe and effective treatments. Strategies for vaccine development include complete vaccines against viruses, subunits, and nucleic acids, but are still in their early stages. Studies carried out to date on possible SARS-CoV2 drug targets highlight glycoprotein S, Mpro (main protease or protease type 3C), and a member of the transmembrane serine protease II families (TMPRSS2). However, due to the pandemic state, priority is given to marketed drugs. These include chloroquine (CQ), hydroxychloroquine (HCQ), nitazoxanide, remdesivir, Lopinavir/ritonavir (LPV / r), in addition to treatment with convalescent plasma. But, therapeutic specific effects against SARS-CoV2 have not yet been verified. Most of the information obtained about treatment is based on preliminary and limited studies. We conclude that, at this time of emergency, the search for new therapies is more urgent due to the need to save lives. Thus, we point out as interesting targets for future more specific research: glycoprotein S, Mpro, and TMPRSS2.

25 June 2018 in Revista de Patologia Tropical / Journal of Tropical Pathology
Verified
Journal Article
Open access
PDF file
COClaudio Bruno Silva de Oliveira
Claudio Bruno Silva de Oliveira
YMYwlliane Meurer
Ywlliane Meurer
VPValeska Santana de Sena Pereira
Valeska Santana de Sena Pereira
JAJoelma Maria de Araújo Andrade
Joelma Maria de Araújo Andrade
JTJuliete Tavares
Juliete Tavares
VAValter Andrade-Neto
Valter Andrade-Neto
Many environmental factors contribute to an effective immune response against Toxoplasma gondii (Tg) infection, among which diet is important in triggering the immune response of the host to infection. Emerging reports suggest that salt intake undermines the regulatory mechanisms mediated by innate and adaptive immune cells. Unfortunately, the impact of an Intermediate Salt Diet (ISD) on the pathogenesis and immune response to toxoplasmosis remains unclear. The purpose of this study was to evaluate the susceptibility profile to an ISD (NaCl 2%) of two mouse strains (outbred Swiss and inbred C57BL6) infected by the ME49 strain of Tg. Our data confirm an antagonistic susceptibility to oral Tg infection among the two mouse strains. Sodium intake induced the highest mortality in C57BL6 compared to Swiss mice in the infected groups. A simultaneous ISD with the infection did not induce significant differences in body weight in either mouse strains. Both mouse strains showed an antagonistic response to a sodium intake diet on the number of parasite brain cysts. An increased number of brain cysts in C57BL6 ISD-Tg animals were noted while Swiss ISD-Tg animals presented a decrease in the number of brain cysts compared to NSD-Tg (Normal Salt Diet) for both mouse strains. Furthermore, sodium intake caused a significant reduction in the specific humoral immune response against Tg in inbred C57BL6 mice. Thus, our data reveal that an ISD affects the humoral immune response in the murine model and influences the course of Tg infection.

1 January 2024 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
COClaudio Bruno Silva de Oliveira
Claudio Bruno Silva de Oliveira
JAJoelma Maria de Araújo Andrade
Joelma Maria de Araújo Andrade
Shahina AkterShahina Akter
Shahina Akter
MSMaria Silva
Maria Silva
UFUmberto Laino Fulco
Umberto Laino Fulco
JOJonas Ivan Nobre Oliveira
Jonas Ivan Nobre Oliveira

24 July 2019 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
JUJoão Cláudio da Costa Urbano
João Cláudio da Costa Urbano
RLRanny Beatriz de Carvalho Holanda Leite
Ranny Beatriz de Carvalho Holanda Leite
RCRenan Leopoldo Pereira Castro
Renan Leopoldo Pereira Castro
CSClarice Maux Vianna da Silva
Clarice Maux Vianna da Silva
JAJoelma Maria de Araújo Andrade
Joelma Maria de Araújo Andrade
CHCecília Maria de Carvalho Xavier Holanda
Cecília Maria de Carvalho Xavier Holanda
Purpose: This study evaluated if Toxoplasma gondii infection and the drug-associated infection modifies the brain radiopharmaceutical Ethylene Cystine Diethylester Dihydrochloride (99mTc-ECD) biodistribution in mice. Materials and methods: A total of 18 mice were divided into 3 groups. Control group (C) received distilled water and 99mTc-ECD; Infected group (I) received T. gondii strain and 99mTc-ECD; Infected and Treated group (IT), in addition to infection, received association of Pyrimethamine and Sulfadiazine and 99mTc-ECD. The T. gondii strain used in this study was TgCkRrRN3. Forty minutes after administration of the 99mTc-ECD, all animals were euthanized, and blood and brain samples were isolated. The counting of the radioactivity percentage per gram of tissue (%ATI/g) was calculated, and statistical analysis was performed by t-test, with a level of significance of p < .05. Results: There was a significant increase in %ATI/g between groups C and I on brain (0.35 ± 0.02 and 0.45 ± 0.04; p = .041) and on blood (0.80 ± 0.09 and 1.14 ± 0.31; p = .049). A significant decrease in %ATI/g occurred between groups C and IT on blood (0.80 ± 0.09 and 0.54 ± 0.08; p = .001) and on brain (0.35 ± 0.02 and 0.22 ± 0.04; p = .049). Conclusions: Combined therapy of anti-Toxoplasma drugs in infected mice reduced the uptake of 99mTc-ECD, probably due to its binding to plasma proteins.